A recent study by Metzger et al. reported systemic inflammation developed in TNBS-induced IBD elevates proinflammatory cytokines levels (TNF-α, IL-6, RANKL) and decreases sclerostin, a known bone formation inhibitor, in osteocytes [91]. This evidence concerns the gene IL6 and inflammatory bowel disease.